Abstract
Purpose Comparison of performance and explainability of a multi-task convolutional deep neuronal network to single-task networks for activity detection in neovascular age-dependent macular degeneration.
Methods From n = 70 patients (46 female, 24 male) who attended the University Eye Hospital Tübingen 3762 optical coherence tomography B-scans (right eye: 2011, left eye: 1751) were acquired with Heidelberg Spectralis, Heidelberg, Germany. B-scans were graded by a retina specialist and an ophthalmology resident, and then used to develop a multi-task deep learning model to predict disease activity in neovascular age-related macular degeneration along with the presence of sub- and intraretinal fluid. We used performance metrics for comparison to single-task networks and visualized the DNN-based decision with t-distributed stochastic neighbor embedding and clinically validated saliency mapping techniques.
Results The multi-task model surpassed single-task networks in accuracy for activity detection (94.2). Further-more, compared to single-task networks, visualizations via t-distributed stochastic neighbor embedding and saliency maps highlighted that multi-task networks’ decisions for activity detection in neovascular age-related macular degeneration were highly consistent with the presence of both sub- and intraretinal fluid.
Conclusions Multi-task learning increases the performance of neuronal networks for predicting disease activity, while providing clinicians with an easily accessible decision control, which resembles human reasoning.
Translational Relevance By improving nAMD activity detection performance and transparency of automated decisions, multi-task DNNs can support the translation of machine learning research into clinical decision support systems for nAMD activity detection.
Competing Interest Statement
FZ has received consulting fees from Allergan, Bayer HealthCare, Boehringer-Ingelheim, Novo Nordisk, MSD and Novartis and speaker fees from Alimera, Allergan, Bayer HealthCare and Novartis. FZ was involved in research funded by grants from Bayer Healthcare, Biogen, Clearside, Ionis, Kodiak, Novartis, Ophtea, Regeneron and Roche/Genentech. LK receives, via third-party accounts of the University Eye Hospital, research funding and honoraria from Novartis and research funding from the Tistou and Charlotte Kerstan Foundation. HF received medical training event costs from Novartis. MSA, WI and GA declare no competing interest.
Funding Statement
Financial support was provided by German Ministry of Science and Education (BMBF) through the Tuebingen AI Center (FKZ 01IS18039A) and the German Science Foundation for funding through a Heisenberg Professorship (BE5601/4-2) and the Excellence Cluster "Machine Learning - New Perspectives for Science" (EXC 2064, project number 390727645), the Junior Clinician Scientist Program of the Faculty of Medicine, Eberhart Karls University of Tuebingen, Germany (application number 463-0-0) (HF) and the Novartis AG. The sponsor or funding organization had no role in the design or conduct of this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the local institutional ethics committee of the University of Tuebingen. Due to the retrospective character of the study, the requirement for patient consent was waived by the ethics committee. The study was conducted in accordance with the tenets of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos